Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in Stock

May 16, 2026 by InsiderTrades.com

Key Points

Millennium Management, a major Sensei Biotherapeutics shareholder, sold 8,151 shares on April 7 at an average price of $31.01, reducing its stake by 5.73%. The filing also shows a mix of other buys and sells in late March and early April.
Sensei Biotherapeutics reported a very weak quarterly result, posting EPS of ($131.45) versus the expected ($0.62). Analysts still see the company losing money, forecasting full-year EPS of -2.77.
Despite the insider activity, the stock has drawn mixed analyst sentiment: ratings range from Buy to Sell, with an average Hold rating and a consensus price target of $40.00.

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder Millennium Management Llc purchased 5,731 shares of the company's stock in a transaction that occurred on Thursday, March 26th. The shares were acquired at an average cost of $28.62 per share, for a total transaction of $164,021.22. Following the completion of the transaction, the insider directly owned 131,370 shares of the company's stock, valued at $3,759,809.40. This trade represents a 4.56% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $25.86 per share, for a total transaction of $246,523.38.
On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $26.61 per share, for a total transaction of $407,691.81.
On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $34.49 per share, for a total transaction of $212,975.75.
On Tuesday, March 31st, Millennium Management Llc bought 6,005 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $28.16 per share, for a total transaction of $169,100.80.
On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ SNSE opened at $20.43 on Friday. The business's 50-day moving average price is $28.89 and its two-hundred day moving average price is $17.87. Sensei Biotherapeutics, Inc. has a one year low of $5.25 and a one year high of $36.76. The company has a market capitalization of $27.38 million, a P/E ratio of -1.23 and a beta of -0.18.

Sensei Biotherapeutics (NASDAQ:SNSE - Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($130.83). On average, equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Trending Headlines about Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Ratings Changes

A number of research analysts have commented on SNSE shares. Weiss Ratings restated a "sell (d-)" rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Zacks Research raised Sensei Biotherapeutics to a "hold" rating in a report on Tuesday, April 21st. Wall Street Zen lowered Sensei Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Leerink Partners assumed coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an "outperform" rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sensei Biotherapeutics presently has an average rating of "Hold" and a consensus price target of $40.00.

Get Our Latest Stock Analysis on SNSE

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 11,516 shares of the company's stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the SEC. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company's lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.